CERO Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CERO Therapeutics's estimated annual revenue is currently $1.7M per year.(i)
  • CERO Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • CERO Therapeutics has 11 Employees.(i)
  • CERO Therapeutics grew their employee count by -31% last year.

CERO Therapeutics's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Sr. DirectorReveal Email/Phone
3
Founder and Chief Technology OfficerReveal Email/Phone
4
Sr. Scientist /Assoc. DirectorReveal Email/Phone
5
Principal ScientistReveal Email/Phone
6
ScientistReveal Email/Phone
7
Principal Scientist - Viral VectorReveal Email/Phone
8
SRAReveal Email/Phone
9
Senior Research AssociateReveal Email/Phone
10
Senior Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is CERO Therapeutics?

At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for oncology. Armed with an understanding of cellular clearance and molecular immunology, we engineer cells to engage new and complementary cell elimination pathways to enable deeper and more sustained clinical responses to maximize wellness.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

-31%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CERO Therapeutics News

2022-04-17 - MarketsandMarkets Biopharma Series - Healthcare Trends, Innovations & Disruptions Under One Roof!

Immune Checkpoint Inhibitors and Combination Therapies. ... Senior Vice President, Head, Translational Medicine, CERo Therapeutics

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M11-31%N/A
#2
$1.7M11N/AN/A
#3
$0.9M11-8%N/A
#4
$0.9M12-76%$38M
#5
$1.9M12-8%N/A